NCT03483311

Brief Summary

• Assessment of tissue level of resolvin D1 in psoriasis in comparison to its level in healthy controls in order to verify its role in the pathogenesis of psoriasis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2018

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

March 23, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 30, 2018

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2018

Completed
Last Updated

March 30, 2018

Status Verified

March 1, 2018

Enrollment Period

6 months

First QC Date

March 23, 2018

Last Update Submit

March 23, 2018

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (1)

  • Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.

    6 months

Study Arms (2)

psoriasis patients

EXPERIMENTAL

Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.

Other: skin biopsy before and after NB-UVB phototherapy

controls

EXPERIMENTAL

Tissue levels of resolvin D1 in controls

Other: skin biopsy before and after NB-UVB phototherapy

Interventions

skin biopsy before and after NB-UVB phototherapyOTHER

skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1

controlspsoriasis patients

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with psoriasis (adults and children above 12years)
  • Both sexes.
  • New cases or cases not receiving any treatment for at least 3 months ago.

You may not qualify if:

  • Any contraindication to phototherapy treatment (e.g. Photosensitizing creams or medications, past skin cancer, especially melanoma, etc...)
  • Erythrodermic and pustular psoriasis.
  • History of autoimmune diseases or other systemic diseases (e.g. Alzheimer's disease, fibromyalgia, cystic fibrosis)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maha Fathy Elmasry

Cairo, 11562, Egypt

RECRUITING

Related Publications (1)

  • Elmasry MF, Hassan E, Rashed LA, Abdel Halim DM. Role of resolvin D1 in psoriasis before and after narrowband ultraviolet B phototherapy: A case-control study. Dermatol Ther. 2021 Mar;34(2):e14879. doi: 10.1111/dth.14879. Epub 2021 Feb 21.

    PMID: 33586174DERIVED

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Maha Elmasry

    Cairo University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Maha Fathy Elmasry, MD

CONTACT

01222633740mahafathy1214@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

March 23, 2018

First Posted

March 30, 2018

Study Start

March 1, 2018

Primary Completion

September 1, 2018

Study Completion

September 1, 2018

Last Updated

March 30, 2018

Record last verified: 2018-03

Locations

EG(1)